| 丙型肝炎直接抗病毒药物耐药相关变异的研究 |
| |
| 引用本文： | 陈建宏,徐小元.丙型肝炎直接抗病毒药物耐药相关变异的研究[J].传染病信息,2016(2):116-120. |
| |
| 作者姓名： | 陈建宏 徐小元 |
| |
| 作者单位： | 北京大学第一医院感染疾病科,100034 |
| |
| 基金项目： | 国家自然科学基金(81373056),国家"十二五"科技重大专项(2012ZX10002003-004-003) |
| |
| 摘 要： | 直接抗病毒药物(direct-acting antiviral agents,DAAs)的应用使慢性丙型肝炎(chronic hepatitis C,CHC)抗病毒治疗进入了新的时代,全口服的DAAs联合治疗方案抗病毒活性强、安全性好且不良反应少。耐药相关变异(resistanceassociated variants,RAV)的出现削弱了DAAs的抗病毒活性,给DAAs的临床应用带来了巨大的挑战。本文将对临床试验和体外研究中检测到的DAAs RAV及其在CHC患者中的自然发生率进行系统的阐述,以期为DAAs治疗效果的预测和治疗方案的选择提供有用的信息。
|
| 关 键 词： | 丙型肝炎 直接抗病毒药物 耐药相关变异 |
Research of HCV variants resistant to direct-acting antiviral agents |
| |
| CHEN Jian-hong,XU Xiao-yuan.Research of HCV variants resistant to direct-acting antiviral agents[J].Infectious Disease Information,2016(2):116-120. |
| |
| Authors: | CHEN Jian-hong XU Xiao-yuan |
| |
| Abstract: | The development of direct-acting antiviral agents (DAAs) leads the antiviral therapy of chronic hepatitis C (CHC) into a new era, and all-oral DAA combination regimens have highly antiviral activity with improved drug safety and reduced side effects. The selection of resistance-associated variants attenuates the antiviral activity of DAAs and brings a great challenge to the clinical application of DAAs. This review provides a systematic elaboration of HCV variants resistant to DAAs observed in clinical trials andin-vitrostudies and their natural prevalence in CHC patients, in the hope of providing useful information for predicting therapeutic efficacy and selecting DAA combination regimens. |
| |
| Keywords: | hepatitis C direct-acting antivirals resistance-associated variants |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
